Thus, based on the concept of CERT1, which is calculated by measuring specific ceramides and ceramide/ceramide ratios in the plasma, the clinical diagnosis of metabolic syndrome seems to be somewhat inaccurate in assessing CVD risk in an obese population. The gene discussed is CERT1; the disease is metabolic syndrome.